公开(公告)号：US20200317665A1

公开(公告)日：2020-10-08

申请号：US16835702

申请日：2020-03-31

Applicant: Array BioPharma Inc.

Inventor： James F. BLAKE ,  Mark Laurence BOYS ,  Mark Joseph CHICARELLI ,  Adam W. COOK ,  Mohamed S. A. ELSAYED ,  Jay Bradford FELL ,  John P. FISCHER ,  Ronald Jay HINKLIN ,  Yutong JIANG ,  Oren T. MCNULTY ,  Macedonio J. MEJIA ,  Martha E. RODRIGUEZ ,  Christina E. WONG

IPC: C07D471/04 ,  C07D401/14 ,  C07D513/10 ,  C07D471/10 ,  A61P35/00

Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：US20220313676A1

公开(公告)日：2022-10-06

申请号：US17108528

申请日：2020-12-01

Applicant: Array Biopharma Inc.

Inventor： Steven W. ANDREWS ,  Sean ARONOW ,  James F. BLAKE ,  Barbara J. BRANDHUBER ,  James COLLIER ,  Adam COOK ,  Julia HAAS ,  Yutong JIANG ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. MCFADDIN ,  Megan L. MCKENNEY ,  Oren T. MCNULTY ,  Andrew T. METCALF ,  David A. MORENO ,  Ginelle A. RAMANN ,  Tony P. TANG ,  Li REN ,  Shane M. WALLS

IPC: A61K31/4545 ,  A61K31/4162 ,  C07D471/04 ,  A61P1/00 ,  A61P35/00 ,  A61P35/02 ,  A61K31/444 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P1/12

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20240066029A1

公开(公告)日：2024-02-29

申请号：US18342314

申请日：2023-06-27

Applicant: Array BioPharma, Inc.

Inventor： Steven W. ANDREWS ,  Sean ARONOW ,  James F. Blake ,  Barbara J. BRANDHUBER ,  Adam COOK ,  Julia HAAS ,  Yutong JIANG ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. MCFADDIN ,  Megan L. MCKENNEY ,  Oren T. MCNULTY ,  Andrew T. METCALF ,  David A. MORENO ,  Tony P. TANG ,  Li REN

IPC: A61K31/496 ,  C07D471/04 ,  A61P1/12 ,  A61P35/04 ,  C07D519/00 ,  A61P35/02 ,  A61P35/00 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/551

CPC classification number: A61K31/496 ,  C07D471/04 ,  A61P1/12 ,  A61P35/04 ,  C07D519/00 ,  A61P35/02 ,  A61P35/00 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/551

Abstract: Provided herein are compounds of the Formula I:




and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20230090520A1

公开(公告)日：2023-03-23

申请号：US17530702

申请日：2021-11-19

Applicant: Array BioPharma, Inc.

Inventor： Steven W. ANDREWS ,  Sean ARONOW ,  James F. BLAKE ,  Barbara J. BRANDHUBER ,  Adam COOK ,  Julia HAAS ,  Yutong JIANG ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. MCFADDIN ,  Megan L. MCKENNEY ,  Oren T. MCNULTY ,  Andrew T. METCALF ,  David A. MORENO ,  Tony P. TANG ,  Li REN

IPC: A61K31/496 ,  C07D471/04 ,  A61P1/12 ,  A61P35/04 ,  C07D519/00 ,  A61P35/02 ,  A61P35/00 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/551

Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.